AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women

New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients Clinical trials in women with heavy menstrual bleeding (HMB) associated with uterine fibroids showed a statistically significant reduction in HMB with el... Biopharmaceuticals, FDA AbbVie, Elagolix, Uterine Fibroids
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news